Enorama Pharma AB Working Capital to Net Assets Ratio
Enorama Pharma AB working capital to net assets ratio. Enorama Pharma AB (ERMA) has a Working Capital to Net Assets ratio of 51.3% as of June 2026. Working capital of Skr-25.88 Million (current assets of Skr6.87 Million minus current liabilities of Skr32.74 Million) is measured against net assets of Skr-50.44 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Enorama Pharma AB (ERMA) tangible equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Enorama Pharma AB (2014–2025)
Working capital to net assets ratio of Enorama Pharma AB from 2014 to 2025. This chart shows how Enorama Pharma AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of June 2026, the ratio stands at 51.3%, reflecting working capital of Skr-25.88 Million against net assets of Skr-50.44 Million SEK. See operational self-sufficiency of Enorama Pharma AB to measure how many days the company can operate on defensive assets alone.
Enorama Pharma AB Working Capital to Net Assets Ratio by Year (2014–2025)
Enorama Pharma AB working capital to net assets ratio by year from 2014 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Enorama Pharma AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Enorama Pharma AB asset portfolio.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 101.1% | Skr-23.72 Million | Skr-23.45 Million | Skr8.00 Million | Skr31.71 Million | ▲ +10.5 pp |
| 2024 | 90.6% | Skr7.07 Million | Skr7.80 Million | Skr15.16 Million | Skr8.09 Million | ▲ +76.5 pp |
| 2023 | 14.1% | Skr2.75 Million | Skr19.54 Million | Skr12.96 Million | Skr10.22 Million | ▲ +16.2 pp |
| 2022 | -2.1% | Skr-674.00K | Skr31.52 Million | Skr11.75 Million | Skr12.43 Million | ▼ -52.4 pp |
| 2021 | 50.3% | Skr10.73 Million | Skr21.35 Million | Skr22.41 Million | Skr11.68 Million | ▲ +376.0 pp |
| 2020 | -325.8% | Skr-5.79 Million | Skr1.78 Million | Skr12.82 Million | Skr18.61 Million | ▼ -431.8 pp |
| 2019 | 106.0% | Skr7.61 Million | Skr7.18 Million | Skr18.02 Million | Skr10.40 Million | ▲ +85.0 pp |
| 2018 | 21.0% | Skr3.57 Million | Skr17.02 Million | Skr18.28 Million | Skr14.71 Million | ▲ +61.4 pp |
| 2017 | -40.4% | Skr-2.98 Million | Skr7.36 Million | Skr2.10 Million | Skr5.08 Million | ▼ -71.6 pp |
| 2016 | 31.1% | Skr2.83 Million | Skr9.08 Million | Skr3.97 Million | Skr1.15 Million | ▲ +46.5 pp |
| 2015 | -15.4% | Skr-1.00 Million | Skr6.52 Million | Skr1.09 Million | Skr2.09 Million | ▲ +5.6 pp |
| 2014 | -21.0% | Skr-558.00K | Skr2.66 Million | Skr26.00K | Skr584.00K | — |